Financial Performance - Revenues for Q3 2025 were approximately $3,334 million, representing a 28.2% increase from approximately $2,601 million in Q3 2024[4] - Gross Profit for Q3 2025 was approximately $392 million, up 21.3% compared to approximately $323 million in Q3 2024[4] - Net income for Q3 2025 was approximately $37.5 million, a turnaround from a net loss of approximately $25.7 million in Q3 2024[4] - Adjusted EBITDA for Q3 2025 was approximately $160 million, reflecting a 37.2% increase from approximately $117 million in Q3 2024[4] - Total revenues for Q3 2025 reached $3,334,106, a 28.1% increase from $2,601,229 in Q3 2024[23] - Gross profit for Q3 2025 was $392,008, up 21.4% from $323,092 in Q3 2024[23] - Operating income for Q3 2025 increased to $87,843, compared to $29,097 in Q3 2024, representing a 201.5% growth[23] - Net income for Q3 2025 was $55,241, a significant recovery from a net loss of $8,981 in Q3 2024[23] - Adjusted EBITDA for Q3 2025 was $160,443, an increase of 37.2% from $116,940 in Q3 2024[25] Guidance and Projections - The company increased its 2025 revenue guidance to between $12,400 million and $12,700 million, indicating growth of 23.1% to 26.1% compared to 2024[4] - Adjusted EBITDA guidance for 2025 was raised to between $605 million and $615 million, representing growth of 31.5% to 33.7%[4] - Pharmacy Segment Revenue is projected to be between $10,950 million and $11,200 million, reflecting growth of 25.1% to 27.9%[4] - Provider Segment Revenue is expected to be between $1,450 million and $1,500 million, indicating growth of 10.0% to 13.8%[4] Balance Sheet and Cash Flow - Cash and cash equivalents as of September 30, 2025, were $140,344, up from $60,954 at the end of 2024[21] - Total assets increased to $6,049,497 as of September 30, 2025, compared to $5,926,140 at the end of 2024[21] - Total current liabilities rose to $1,549,970 as of September 30, 2025, from $1,428,333 at the end of 2024[21] Shareholder Metrics - The company reported a basic income per share of $0.19 for continuing operations in Q3 2025, compared to a loss of $0.13 in Q3 2024[23] - Diluted EPS for Q3 2025 is $0.17, compared to $(0.13) in Q3 2024, showing a significant improvement[27] - Adjusted EPS for Q3 2025 is $0.30, up from $0.03 in Q3 2024, indicating strong operational performance[27] - Adjusted EPS for the nine months ended September 30, 2025 is $0.69, compared to $0.20 in the same period of 2024[27] Costs and Expenses - Non-cash share-based compensation increased to $0.07 in Q3 2025 from $0.06 in Q3 2024[27] - Acquisition, integration, and transaction-related costs decreased to $0.03 in Q3 2025 from $0.06 in Q3 2024[27] - Restructuring and divestiture-related costs remained stable at $0.06 for both Q3 2025 and Q3 2024[27] - The income tax impact on adjustments for Q3 2025 was $(0.03), compared to $(0.06) in Q3 2024[28] - Legal costs and settlements were $0.04 in Q3 2024, with no impact reported in Q3 2025[27] Business Strategy - The company plans to divest its Community Living business to Sevita, with the transaction expected to close in early Q1 2026[4] - The leverage ratio was approximately 3.31x as of September 30, 2025, including the results of the Community Living business in the calculation[4] Share Count - The weighted average common shares outstanding for diluted EPS calculation was 217,982 thousand in Q3 2025, compared to 198,491 thousand in Q3 2024[27] - The weighted average common shares outstanding for diluted Non-GAAP income per share was 218,519 thousand in Q3 2025, compared to 199,930 thousand in Q3 2024[27]
Brightspring Health Services, Inc.(BTSGU) - 2025 Q3 - Quarterly Results